ID16266A - Perlakuan dan pencegahan pankreatitis - Google Patents

Perlakuan dan pencegahan pankreatitis

Info

Publication number
ID16266A
ID16266A IDP970826A ID970826A ID16266A ID 16266 A ID16266 A ID 16266A ID P970826 A IDP970826 A ID P970826A ID 970826 A ID970826 A ID 970826A ID 16266 A ID16266 A ID 16266A
Authority
ID
Indonesia
Prior art keywords
prevention
treatment
pancreatitical
troglitazone
pancreatitis
Prior art date
Application number
IDP970826A
Other languages
English (en)
Indonesian (id)
Inventor
Toshihiko Fujiwara
Hiroyoshi Horikoshi
Masaharu Fukami
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of ID16266A publication Critical patent/ID16266A/id

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Catching Or Destruction (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IDP970826A 1996-03-18 1997-03-14 Perlakuan dan pencegahan pankreatitis ID16266A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6106396 1996-03-18
JP25020196 1996-09-20

Publications (1)

Publication Number Publication Date
ID16266A true ID16266A (id) 1997-09-18

Family

ID=26402115

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP970826A ID16266A (id) 1996-03-18 1997-03-14 Perlakuan dan pencegahan pankreatitis

Country Status (18)

Country Link
US (1) US5753681A (de)
EP (1) EP0796618B1 (de)
KR (1) KR100542778B1 (de)
CN (1) CN1178657C (de)
AT (1) ATE212548T1 (de)
AU (1) AU708315B2 (de)
CA (1) CA2200126C (de)
CZ (1) CZ283968B6 (de)
DE (1) DE69710111T2 (de)
DK (1) DK0796618T3 (de)
ES (1) ES2167678T3 (de)
HU (1) HUP9700598A3 (de)
ID (1) ID16266A (de)
IL (1) IL120443A (de)
NO (1) NO313179B1 (de)
NZ (1) NZ314406A (de)
PT (1) PT796618E (de)
TW (1) TW548102B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
PT1022272E (pt) * 1997-10-08 2004-08-31 Sankyo Co Compostos heterociclicos fundidos substituidos
CN1130361C (zh) 1998-03-30 2003-12-10 日本烟草产业株式会社 异噁唑烷二酮化合物的制备方法
CN1312807A (zh) 1998-06-19 2001-09-12 希龙公司 糖元合成酶激酶3的抑制剂
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
KR20010079551A (ko) * 1998-07-21 2001-08-22 피터 기딩스 아폽토시스를 감소시키기 위한 글루코즈 업테이크증진제의 용도
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
EP1196189A2 (de) * 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Unterschiedliche wirkstoffe für diabetestherapie
KR100738245B1 (ko) 1999-08-23 2007-07-12 교린 세이야꾸 가부시키 가이샤 치환된 벤질티아졸리딘-2,4-디온 유도체
KR100700304B1 (ko) 1999-08-23 2007-03-29 교린 세이야꾸 가부시키 가이샤 치환된 벤질티아졸리딘-2,4-디온 유도체
US6452014B1 (en) * 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
EP2413967A1 (de) 2009-04-01 2012-02-08 F. Hoffmann-La Roche AG Behandlung von insulinresistenten erkrankungen

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
DE3343141A1 (de) * 1983-11-29 1985-06-05 Hermann P.T. 7400 Tübingen Ammon Verwendung von cystein-derivaten oder deren salzen, zur steigerung der insulinsekretion der langerhans'schen inseln der bauchspeicheldruese
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物,其制备方法和用途
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
HU210339B (en) * 1985-05-21 1995-03-28 Pfizer Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
US5260445A (en) * 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
US5194443A (en) * 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
EP0842925A1 (de) * 1987-09-04 1998-05-20 Beecham Group Plc Substituierte Thiazolidindionderivate
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
DK375789A (da) * 1988-08-18 1990-02-19 Syntex Inc Peptidderivater
JP2845743B2 (ja) * 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
AU7118694A (en) * 1993-07-13 1995-02-13 Janica M. Moizis Fastener for clothing
ATE179709T1 (de) * 1993-12-27 1999-05-15 Japan Tobacco Inc Isoxazolidindionderivate und deren verwendung
RU2151145C1 (ru) * 1994-04-11 2000-06-20 Санкио Компани Лимитед Промежуточное соединение для получения гетероциклических соединений, обладающих антидиабетической активностью
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
FR2721608B1 (fr) * 1994-06-22 1996-07-19 Rhone Poulenc Rorer Sa Dérivés de thiazolidine, leur préparation et les médicaments les contenant.
CA2159938A1 (en) * 1994-10-07 1996-04-08 Hiroaki Yanagisawa Oxime derivatives, their preparation and their therapeutic use
CZ293016B6 (cs) * 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem

Also Published As

Publication number Publication date
NO971219L (no) 1997-09-19
IL120443A (en) 2000-07-16
KR19980023975A (ko) 1998-07-06
DK0796618T3 (da) 2002-05-06
DE69710111T2 (de) 2002-10-02
HK1003051A1 (en) 1998-10-09
TW548102B (en) 2003-08-21
AU708315B2 (en) 1999-07-29
NO971219D0 (no) 1997-03-17
CA2200126C (en) 2006-08-15
KR100542778B1 (ko) 2006-04-14
CZ283968B6 (cs) 1998-07-15
CZ79097A3 (en) 1997-10-15
CN1178657C (zh) 2004-12-08
EP0796618B1 (de) 2002-01-30
CA2200126A1 (en) 1997-09-18
CN1170575A (zh) 1998-01-21
NZ314406A (en) 2000-12-22
HU9700598D0 (en) 1997-05-28
DE69710111D1 (de) 2002-03-14
AU1628597A (en) 1997-09-25
HUP9700598A3 (en) 1998-10-28
ES2167678T3 (es) 2002-05-16
HUP9700598A2 (hu) 1998-09-28
PT796618E (pt) 2002-06-28
ATE212548T1 (de) 2002-02-15
IL120443A0 (en) 1997-07-13
US5753681A (en) 1998-05-19
MX9702058A (es) 1998-03-31
EP0796618A1 (de) 1997-09-24
NO313179B1 (no) 2002-08-26

Similar Documents

Publication Publication Date Title
ID16266A (id) Perlakuan dan pencegahan pankreatitis
DK0572166T3 (da) Hidtil ukendte 7beta-substitueret-4-aza-5beta-androstan-3-oner som 5beta-reduktaseinhibitorer
HU9402342D0 (en) Phosphono-oxymethyl-ethers of taxane derivatives
LU91271I2 (fr) Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)
EP0908186A3 (de) Verfahren zur Schmerzbehandlung
FI905531A0 (fi) Transdermalisk anvaendning av 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobensotiazol.
ATE253063T1 (de) 5-ht1f-agonisten
ATE215530T1 (de) 7-substituierte-8-substituierte-9-substituierte amino-7-demethyl-6-deoxy-tetracycline als antibiotische mittel
ATE238790T1 (de) Verwendung von pramipexole als neuroschutzmittel
MA23603A1 (fr) Derives d'oxalylamino-benzafuranne et benzothienyle.
PT991416E (pt) Plasma sanguineo universalmente aplicavel
DE69825605D1 (de) Behandlung der schizophrenie und der psychose
ID25478A (id) Agonis 5-ht1f
TR199600117A2 (tr) Ikame edilen benzolsülfonilüre ve tiyoüre, bu maddelerin elde edilmesi ve eczanecilikle ilgili maddelerin bu bilesimler ve bu bilesimleri iceren iyilestirici maddelere dayanarak kullanilmasi ile ilgili usul.
NO973003D0 (no) Synergistiske kombinasjoner av 2-(tiocyanometyltio)benzotiazol- og -tiofanatforindelser anvendelige som fungicider
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
MX9704035A (es) 1,1-dioxidos de 2-(fosfiniloximetil)-1,2,5-tiadiazolidin-3-ona substituidos y composiciones y metodo de uso de los mismos.
IT1303621B1 (it) Nastro trasportatore per il trattamento di materiali.
ES2185154T3 (es) Metodo de uso de inhibidores de la ciclooxigenasa-2 en el tratamiento y prevencion de la demencia.
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin
ATE262527T1 (de) Zur vorbeugung oder behandlung von östrogenabhängigen krankheiten nützliche pyrrolo(2.1.5-cd)indolizin-derivate
GR3036968T3 (en) Adamantyl substituted oxindoles as pharmaceutical agents
ZA971413B (en) Novel substituted n-methyl-n-(4-(piperindin-1-yl)-2(aryl) butyl)benzamines useful for the treatment of allergic diseases.